AMGN Amgen Inc stock chart & analysis
Conviction 40HealthcareScan · Fri, Nov 6, 2026Amgen Inc (AMGN) closed at $460.42 (+0.03%) on Nov 6, 2026. Price is above its 50-day and above its 200-day moving average. RSI(14) 60, RS Rating 92, -4.9% from its 52-week high, +40.6% year to date. Sector: Healthcare · Biological Products, (No Diagnostic Substances).
Financials as of Wed, Sep 30, 2026 · quarterly.
AMGN technical analysis
Trend
AMGN is in an uptrend: price is above the 50-day, which is above the 200-day moving average. It closed 9.0% above the 50-day ($422.43) and 21.8% above the 200-day ($378.01). ADX(14) at 39 points to a strong, established trend. It meets 8 of 8 trend-template criteria.
Momentum
RSI(14) is 60, in the bullish half of its range. The MACD histogram is positive. Its RS Rating of 92 puts its weighted 12-month performance ahead of about 92% of the US market, and its RS line is at a new high.
Volume and volatility
Volume on the latest session ran 0.9× its 20-day average. It trades about $1.3B a day on average. ATR(14) is $12.73, 2.8% of price — its typical daily range. On-balance volume is trending up. Chaikin Money Flow (-0.09) shows distribution.
Key levels
The chart pattern's support is $385.24 and its resistance $463.31. The 52-week range is $312.39 to $483.99; price is 4.9% below the high and 47.4% above the low. The VWAP anchored at the 52-week high is $463.74, above price.
Performance
AMGN returned -1.2% (1 week), +13.0% (1 month), +10.3% (3 months), +38.8% (6 months), +43.9% (1 year), +40.6% (year to date).
About Amgen Inc
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
Biological Products, (No Diagnostic Substances) · Listed 1983 · 31,500 employees
Signal lifecycle
How this symbol has moved through the lanes across 60 scans — each scan is re-classified from that day's price, so gaps are days it dropped off the board entirely.
- Setting upOct 20 – Oct 212 scans
- Breaking out nowOct 221 scan
Congress activity
Disclosed STOCK Act trades in AMGN · 10 recent
| Member | Side | Amount | Traded | Filed | PTR |
|---|---|---|---|---|---|
 David J. Taylor house · R · OH · traded 2026-09-22 | Buy | $1K–$15K | 2026-09-22 | 2026-10-01 | |
David J. Taylor house · R · OH · traded 2026-08-26 | Sell | $1K–$15K | 2026-08-26 | 2026-09-05 | |
 Sheldon Whitehouse senate · D · RI · traded 2026-08-12 | Sell | $1K–$15K | 2026-08-12 | 2026-09-02 | |
 Thomas H Tuberville senate · traded 2025-04-15 | Sell | $15K–$50K | 2025-04-15 | 2026-08-05 | |
 Alan Armstrong senate · R · OK · traded 2026-03-27 | Sell | $15K–$50K | 2026-03-27 | 2026-07-21 | |
David J. Taylor house · R · OH · traded 2026-06-05 | Buy | $1K–$15K | 2026-06-05 | 2026-06-12 | |
David J. Taylor house · OH · traded 2026-02-26 | Sell | $1K–$15K | 2026-02-26 | 2026-03-05 | |
David J. Taylor house · OH · traded 2026-01-16 | Buy | $1K–$15K | 2026-01-16 | 2026-01-30 | |
David J. Taylor house · OH · traded 2025-12-03 | Sell | $1K–$15K | 2025-12-03 | 2025-12-05 | |
 Marjorie Taylor Greene house · GA · traded 2025-10-24 | Buy | $1K–$15K | 2025-10-24 | 2025-10-28 |
Insider activity
SEC Form 4 transactions in AMGN · open-market 2 sells
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Khosla Rachna SVP, Business Development · Nqso (Right to Buy) · 2026-08-13 | Exercise | 1.25K | — | 2026-08-13 | 2026-08-13 |
Khosla Rachna SVP, Business Development · Common Stock · 2026-08-13 | Sell | 1.25K | $521K | 2026-08-13 | 2026-08-13 |
Khosla Rachna SVP, Business Development · Common Stock · 2026-08-13 | Exercise | 1.25K | $204K | 2026-08-13 | 2026-08-13 |
Khosla Rachna SVP, Business Development · Common Stock · 2026-08-11 | Sell | 2K | $825K | 2026-08-11 | 2026-08-13 |
Busch Matthew C. VP, Finance & CAO · Common Stock · 2026-08-07 | Grant | 730 | — | 2026-08-07 | 2026-08-12 |
ISHRAK OMAR Director · Common Stock · 2026-08-07 | Grant | 85.169 | — | 2026-08-07 | 2026-08-10 |
HOLLEY CHARLES M Director · Common Stock · 2026-08-07 | Grant | 103.419 | — | 2026-08-07 | 2026-08-10 |
Drake Michael V Director · Common Stock · 2026-08-07 | Grant | 63.876 | — | 2026-08-07 | 2026-08-10 |
Miller Derek SVP, Human Resources · Common Stock · 2026-08-06 | Exercise | 2.07K | $336K | 2026-08-06 | 2026-08-07 |
Miller Derek SVP, Human Resources · Common Stock · 2026-08-06 | Exercise | 1.82K | $323K | 2026-08-06 | 2026-08-07 |
SEC filings
EDGAR filings in AMGN · 10 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.
Start free — 7-day trial, no card →Free daily signals by email. Top 3 setups per lane after every close. No account needed.
Unsubscribe anytime · Privacy
Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.